BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38102464)

  • 1. SOCS3 inhibiting JAK-STAT pathway enhances oncolytic adenovirus efficacy by potentiating viral replication and T-cell activation.
    Yan D; Li G; Yuan Y; Li H; Cao H; Dai Y; Li Y; Zhang Z; Li F; Fang Y; Gao Q
    Cancer Gene Ther; 2024 Mar; 31(3):397-409. PubMed ID: 38102464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfer of suppressor of cytokine signaling 3 by an oncolytic adenovirus induces potential antitumor activities in hepatocellular carcinoma.
    Cui Q; Jiang W; Wang Y; Lv C; Luo J; Zhang W; Lin F; Yin Y; Cai R; Wei P; Qian C
    Hepatology; 2008 Jan; 47(1):105-12. PubMed ID: 17935223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioreducible polymer-mediated delivery of oncolytic adenovirus can attenuate antiviral immune response and concurrently enhance the induction of antitumor immune response to effectively prevent metastasis.
    Kasala D; Lee SH; Hong J; Oh E; Yoon AR; Yun CO
    Biomater Sci; 2022 Jul; 10(15):4293-4308. PubMed ID: 35766864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
    Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms.
    Lahera A; López-Nieva P; Alarcón H; Marín-Rubio JL; Cobos-Fernández MÁ; Fernández-Navarro P; Fernández AF; Vela-Martín L; Sastre I; Ruiz-García S; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
    Br J Haematol; 2023 May; 201(4):718-724. PubMed ID: 36786170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide renders murine cancer cells susceptible to oncolytic adenovirus replication and oncolysis.
    Garza-Morales R; Yaddanapudi K; Perez-Hernandez R; Riedinger E; McMasters KM; Shirwan H; Yolcu E; Montes de Oca-Luna R; Gomez-Gutierrez JG
    Cancer Biol Ther; 2018 Mar; 19(3):188-197. PubMed ID: 29252087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal Stem Cell-Mediated Delivery of an Oncolytic Adenovirus Enhances Antitumor Efficacy in Hepatocellular Carcinoma.
    Yoon AR; Hong J; Li Y; Shin HC; Lee H; Kim HS; Yun CO
    Cancer Res; 2019 Sep; 79(17):4503-4514. PubMed ID: 31289131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
    de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
    J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dopamine antagonist, domperidone enhances the replication of an oncolytic adenovirus in human tumour cells.
    Nishimae F; Sakurai F; Ono R; Onishi R; Takayama K; Mizuguchi H
    J Gen Virol; 2022 Jun; 103(6):. PubMed ID: 35731650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
    Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
    Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Novel Oncolytic Adenovirus Expressing a Short-hairpin RNA Against Cullin 4A.
    Wakabayashi K; Sakurai F; Ono R; Fujiwara T; Mizuguchi H
    Anticancer Res; 2020 Jan; 40(1):161-168. PubMed ID: 31892564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response.
    Jung BK; Oh E; Hong J; Lee Y; Park KD; Yun CO
    Biomaterials; 2017 Dec; 147():26-38. PubMed ID: 28923683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
    Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
    Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor effect mediated by a paclitaxel-conjugated polymeric micelle-coated oncolytic adenovirus.
    Kasala D; Lee SH; Hong JW; Choi JW; Nam K; Chung YH; Kim SW; Yun CO
    Biomaterials; 2017 Nov; 145():207-222. PubMed ID: 28869866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration.
    Na Y; Nam JP; Hong J; Oh E; Shin HC; Kim HS; Kim SW; Yun CO
    J Control Release; 2019 Jul; 305():75-88. PubMed ID: 31071373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment.
    Nguyen TT; Ramsay L; Ahanfeshar-Adams M; Lajoie M; Schadendorf D; Alain T; Watson IR
    Clin Cancer Res; 2021 Jun; 27(12):3432-3442. PubMed ID: 33593882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic role of microRNA-19b-3p-mediated SOCS3 in glioma through activation of JAK-STAT pathway.
    Li T; Ge H; Yang Q; Wang J; Yin Q; Wang H; Hou G
    Metab Brain Dis; 2023 Mar; 38(3):945-960. PubMed ID: 36484970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer.
    Yoon AR; Jiao A; Hong J; Kim B; Yun CO
    Front Immunol; 2024; 15():1360436. PubMed ID: 38812516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer targeting gene-viro-therapy specific for liver cancer by α-fetoprotein-controlled oncolytic adenovirus expression of SOCS3 and IL-24.
    Cao X; Wei R; Liu X; Zeng Y; Huang H; Ding M; Zhang K; Liu XY
    Acta Biochim Biophys Sin (Shanghai); 2011 Oct; 43(10):813-21. PubMed ID: 21835849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.